(1 - 12 von 13
)
BioCardia and Juventas to start phase II trial for heart failure treatmentcardiovascularnews.com › News
cardiovascularnews.com
· ... I clinical trial and is an attractive delivery system for our targeted patient population,” said Rahul Aras, president and CEO Juventas.
BioCardia and Juventas Announce Phase II Development Program of...
www.finanznachrichten.de
BioCardia, a leading provider of cardiovascular catheter systems designed to deliver biologic therapies for cardiac regeneration and Juventas The…utics, a...
Phase II STOP-HF study of JVS-100 in patients with symptomatic heart...
cardiovascularnews.com
“Completing enrolment of STOP-CLI and STOP-HF are significant milestones for the company this year,” states Rahul Aras, president and CEO for Juventas The…utics. “To date, more than 120 patients have received JVS-100 therapy and we are building a strong safety profile. Next year is an important ...
Iterion to begin Phase I tegavivint trial in lung cancer later this yearwww.clinicaltrialsarena.com › news › iterion-the…...
· Iterion The…utics will trial its lead candidate tegavivint in non-small cell lung cancer by the end of the year, CEO Rahul Aras said.
sortiert nach Relevanz / Datum